Aurora Cannabis Introduces the Company's First Inhalable Resin Cartridges for Patients in the United Kingdom

Rhea-AI Summary

Aurora Cannabis (NASDAQ: ACB) has launched its first medical cannabis concentrates for patients in the United Kingdom, expanding its global medical cannabis portfolio. The company introduced two proprietary cultivar-specific 1.2g resin cartridges: Sourdough (indica) and Electric Honeydew (sativa).

The inhalable cartridges offer key benefits including exceptional flavor profiles, high potency for consistent dosing, and a user-friendly design for convenient and discreet consumption. The products are manufactured in TGA-GMP certified facilities without additives, ensuring premium quality and safety standards.

This launch follows successful implementations in Canada and Australia, demonstrating Aurora's commitment to expanding patient access to high-quality medical cannabis globally. The products are available nationwide through cannabis retailers, with patients advised to consult their doctors or clinics for more information.

Positive

• Expansion into UK market with new medical cannabis product category
• Product portfolio diversification with high-margin concentrates
• TGA-GMP certified manufacturing ensuring premium quality standards
• Geographic expansion of existing successful product line from Canada and Australia

Negative

• None.

News Market Reaction

-0.47%

1 alert

-0.47% News Effect

On the day this news was published, ACB declined 0.47%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NASDAQ | TSX: ACB

Canada's Leading Medical Cannabis Company Expands Patient Offering with Innovative Dosage Solution

EDMONTON, AB, April 15, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has announced today the availability of medical cannabis concentrates to patients in the United Kingdom (UK). This launch marks the company's meaningful step in offering its proprietary cultivar-specific inhalable cannabis extracts in the UK market. These products are available to patients in Canada and Australia and this launch reinforces Aurora's commitment to expanding patient access to an even greater variety of high-quality, premium medical cannabis globally.

"As a company dedicated to patient care and ensuring we regularly listen to patient feedback – we recognized a real need for a convenient, and discreet consumption option and are excited to introduce a new cannabis format at a promised level of quality," said Trisha Cassidy, Managing Director Aurora UK and Ireland. "Our launch of inhalable cannabis cartridges are another step forward in our mission to provide physicians with a larger variety of high-quality medical cannabis that can meet the growing needs and wishes of patients here in the UK. We look forward to receiving feedback from physicians and patients with this expanded offering."  

The two novel cultivar-specific Aurora 1.2g resin cartridges have been developed from two highly sought-after proprietary cultivars: Sourdough (indica) and Electric Honeydew (sativa). The inhalation method of these cartridges offers an ideal solution for fast and controlled delivery of medical cannabis.

Key benefits of cannabis inhalers include:

• Exceptional Flavour Profiles: Connected to popular flower products, these strain-specific cartridges use high-quality terpenes and pure extracts to deliver rich and authentic flavours.
• High Potency: Ensures a powerful, consistent, controllable experience with each dose.
• Safety and Quality: Manufactured in state-of-the-art facilities, adhering to strict TGA-GMP quality control and safety standards. These cartridges contain no additives, representing the pinnacle of cannabis purity.
• User-Friendly Design: Easy to use, making it a convenient, portable and discreet choice for patients.

Aurora's industry-leading portfolio of cannabis products is available nationwide for cannabis retailers to offer. Patients may contact their clinic for further information or consult their doctor.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at   www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Contact

For Media: Michelle Lefler | VP, Communications & PR | media@auroramj.com

For Investors: ICR, Inc. | aurora@icrinc.com

Forward Looking Information:  

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's launch of medical cannabis concentrates to patients in the United Kingdom, the availability of those products in that market, and the Company's commitment to expanding patient access to an even greater variety of high-quality, premium cannabis.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-introduces-the-companys-first-inhalable-resin-cartridges-for-patients-in-the-united-kingdom-302428202.html

SOURCE Aurora Cannabis Inc.

FAQ

What new products has Aurora Cannabis (ACB) launched in the UK market?

Aurora Cannabis has launched two 1.2g resin cartridges: Sourdough (indica) and Electric Honeydew (sativa) strains, marking their first inhalable cannabis products in the UK market.

What are the key features of Aurora's (ACB) new cannabis cartridges?

The cartridges feature high potency, strain-specific terpenes, pure extracts, no additives, and are manufactured under TGA-GMP standards with a user-friendly design for controlled dosing.

Where else are Aurora's (ACB) cannabis cartridges available besides the UK?

Aurora's cannabis cartridges are also available to patients in Canada and Australia.

How can UK patients access Aurora's (ACB) new cannabis cartridges?

Patients can access the products through cannabis retailers nationwide and should consult their doctor or clinic for more information.